The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Clinicopathologic features of advanced RET fusion-positive lung cancers and outcomes in comparison to other fusion-positive lung cancers.
Alexander E. Drilon
No relevant relationships to disclose
Matthew David Hellmann
No relevant relationships to disclose
Lu Wang
No relevant relationships to disclose
Eun Jung Cho
No relevant relationships to disclose
Marc Ladanyi
Stock Ownership - Foundation Medicine
Naiyer A. Rizvi
No relevant relationships to disclose